Research Reports

Prepared Highlights

Q2 2025 reported revenue decreased 0.4% YoY to $797.4M, with organic revenue decline of 7.0% (prepared)
BSI segment organic revenue declined 7.2% in Q2; BEST segment organic revenue declined 4.8% net of intercompany eliminations (prepared)
Q2 non-GAAP gross margin decreased 270 bps to 48.6%; non-GAAP operating margin was 9.0%, down 480 bps YoY (prepared)
Q2 non-GAAP diluted EPS was $0.32, down 38.5% from $0.52 in Q2 2024 (prepared)
First half 2025 revenue increased 5.0% to $1.60B; first half organic revenue declined 2.3% (prepared)
First half 2025: BioSpin revenue $403M (flat YoY); CALID revenue $566M (low-teens growth); Bruker Nano revenue $509M (low single-digit growth); BEST revenue declined low-teens (prepared)
BSI segment book-to-bill ratio in Q2 was in the mid 0.9 range (CEO)
Free cash outflow of $110M in first half 2025 (CFO)
Expanded cost savings initiative targeting $100M to $120M annualized cost reductions, majority expected in FY2026 (CEO, CFO)
Official guidance (FY2025): Revenue range $3.43B to $3.50B; organic revenue decline 2% to 4%; reported revenue growth 2% to 4%; non-GAAP EPS range $1.95 to $2.05 (down 15% to 19% YoY) (CFO)
Q3 2025 outlook: Mid- to high-single-digit organic revenue decline YoY; non-GAAP EPS similar to Q2 2025 (CFO)

Mgmt Quotes

"Life Science research instruments markets are under pressure at the moment with expected U.S. academic funding headwinds and China stimulus delays for high-end research instrumentation." (CEO)
"We are announcing a significantly expanded cost savings initiative that is expected to reduce our annual costs for fiscal year 2026 by $100 million to $120 million annualized." (CEO)
"Our second quarter '25 non-GAAP operating margin was 9%, a decrease of 480 bps year-over-year as lower revenue absorption, additional tariff costs and currency headwinds were only partially mitigated." (CEO)
"These cost actions are expected to contribute approximately 300 basis points of operating margin improvement in fiscal year '26, even under flat or muted market demand conditions." (CFO)
"We expect a very significant EPS rebound in fiscal year '26 based on our significant cost-cutting initiatives with or without meaningful revenue growth." (CFO)

Prepared Metrics

Metric	Value	Speaker/Context
Q2 2025 Reported Revenue	$797.4M	Prepared
Q2 2025 Organic Revenue Decline	-7.0%	Prepared
Q2 2025 Non-GAAP Gross Margin	48.6%	Prepared
Q2 2025 Non-GAAP Operating Margin	9.0%	Prepared
Q2 2025 Non-GAAP Diluted EPS	$0.32	Prepared
First Half 2025 Revenue	$1.60B	Prepared
First Half 2025 Organic Revenue Decline	-2.3%	Prepared
First Half 2025 Free Cash Flow	-$110M	CFO
FY2025 Revenue Guidance	$3.43B – $3.50B	CFO
FY2025 Organic Revenue Decline Guidance	-2% to -4%	CFO
FY2025 Non-GAAP EPS Guidance	$1.95 – $2.05	CFO
FY2026 Annualized Cost Savings Target	$100M – $120M	CEO, CFO

Q&A Batch (1-5 of 5)

Q1 — Puneet Souda

Topic: 订单积压、Q4复苏及FY26展望；UHF磁体与MALDI渠道影响
Key points:
- 积压月数从7个月降至6.5个月；Q4复苏目标“看似可行”，但Q3仍将偏弱。
- FY26尚无明确指引，管理层强调即使在零增长情景下也能实现“显著的利润率扩张和EPS增长”。
- UHF磁体：Q3无收入确认，Q4预计有1笔。
- 关于BD微生物业务被收购：MALDI Biotyper渠道可能受影响，但管理层认为直接销售可替代，且诊断业务中90%为检测与法规内容。
Mgmt stance: 中性偏谨慎；对Q4信心中等，但强调缺乏对FY26的清晰可见性（尤其受美国联邦预算影响）；对渠道变化持开放态度但无明确预期。

Q2 — Tycho W. Peterson

Topic: 成本削减计划的时间与承诺；2026年增长前景变化；杠杆率
Key points:
- 当前EPS比90天前低30%，其中仅$0.05来自外汇。
- 成本削减计划分阶段实施：初期$2500万，关税后扩至$5000万+；2025年约有$3000万成本节省生效。
- 管理层重申对$1亿-$1.2亿成本节省目标的完全承诺，且不考虑市场条件。
- 2026年增长预期从6月会议的2%-4%下调至“尚不明确”；主要变化包括美国生物制药高端仪器订单放缓及欧洲/美国/中国工业研究投资疲软。
- 杠杆率目前超过4倍，契约要求3.5倍；目标为2.7倍，但“需要数年”达成。
Mgmt stance: 中性偏防御；对成本削减承诺坚定，但对2026年增长持谨慎态度（无复苏假设）；杠杆率在可控范围但需时间降至目标。

Q3 — Brandon Couillard

Topic: Q2自由现金流消耗与下半年现金流展望；资本支出下降原因；BSI售后市场表现
Key points:
- Q2存在$5000万-$6000万的“一次性”税项流出（预付款），预计不会重复。
- 下半年资本支出计划下调，因上半年已有既定项目。
- BSI售后市场季度环比持平；其中ELITech分子诊断平台安装量“远超计划”，构成未来消耗品收入。
- 诊断业务80%-90%为消耗品性质，MALDI Biotyper消耗品表现良好。
Mgmt stance: 中性偏积极；认为现金流将恢复正常；对ELITech诊断业务的安装增长表示乐观。

Q4 — Luke England Sergott

Topic: 中国刺激资金动态与2026年增长情景；美国学术资金（NIH/NSF）前景
Key points:
- 中国高端研究仪器刺激资金尚未释放，但7月正常招标活动略微增强；客户对刺激释放“非常乐观”，但具体时间不明。
- 2026年“温和增长”情景假设至少比当前（营收下降2%-4%）好转，但不会恢复至6%-8%的有机增长。
- 预期进入2026年后，关税稳定与贸易秩序明朗化将缓解企业对资本支出的谨慎态度。
- 美国学术基金：NIH预计不会持平或上涨，大概率下降10%-20%；NSF 2025年已有大型NMR招标活动但尚未决定。
Mgmt stance: 谨慎乐观；对中国刺激延迟但最终会释放有信心；对2026年增长不做量化承诺，但预期比2025年改善。

Q5 — Subhalaxmi T. Nambi

Topic: 2025年全年指引的损益表桥接（成本削减 vs. 逆风）
Key points:
- 2025年全年约$3000万成本节省将在Q4集中体现；大部分节省（超出此部分）将落在2026年。
- 2025年成本节省被有机收入下降2%-4%、外汇及关税逆风“淹没”。
- Q4将是全年表现最强的季度（因$3000万节省主要在此季度生效）。
Mgmt stance: 中性；承认成本削减规模不足以完全对冲2025年逆风，但强调Q4环比将明显改善。

Q&A Batch (6-9 of 9)

Q6 — Daniel Gregory Brennan

Topic: NIH budget outlook and backlog dynamics
Key points:
- For fiscal year '25 (calendar year '25), U.S. academic government revenue expected down 20%–25%; first half down ~15%.
- For fiscal year '26, mgmt is prepared for NIH budget down 20% but has no prediction; Senate committee marked up a small increase, administration initially proposed 40% decrease.
- Backlog currently 6.5 months; expected to normalize to ~5 months as mix shifts to more consumables/service.
Mgmt stance: Neutral/cautious on NIH (no prediction, preparing for worst case); neutral on backlog (still elevated but needs bookings to support future growth).

Q7 — Patrick Bernard Donnelly

Topic: Second-half revenue and EPS cadence, especially Q4 ramp
Key points:
- Q4 historically represents ~30% of annual revenue; mgmt expects similar pattern for 2025.
- Q4 EPS implied ~$0.90 (based on Q3 ~$0.32); mgmt says math is “not terribly far off” their estimates.
- Cost savings planned for Q4 will boost operating margin and EPS; revenue expected flat to down in Q4 given market conditions.
Mgmt stance: Bullish on Q4 ramp (historical pattern, cost savings, leverage on volume).

Q8 — Joshua Paul Waldman

Topic: Academic orders by geography and tariff impact on competitive position
Key points:
- Academic order weakness concentrated in U.S. and China; Europe and rest of APAC show no discernible trend.
- Even if U.S. orders come in by September (fiscal year-end), higher-end systems would deliver into '26; no step-up expected in '25.
- Tariffs: no significant competitive distortion; main competitors in spatial biology (U.S.), NMR (Japan), mass spec (Europe/Singapore); Bruker can shift NMR production from Switzerland to Germany/France if needed.
Mgmt stance: Neutral on academic orders (U.S./China weak, no recovery in '25); neutral on tariffs (no competitive shift, just cost headwind).

Q9 — Unidentified Analyst

Topic: Tariff assumptions in guidance
Key points:
- Current tariff assumptions: European Union/Israel 15%, Malaysia 19%, Switzerland modeled at 15%.
- Worst-case Swiss tariff of 39% would be an additional ~$10 million hit, but mgmt considers this unlikely; would shift NMR production from Switzerland to Germany/France.
Mgmt stance: Bullish on tariff modeling (assumes lower Swiss rate; supply chain flexibility mitigates worst case).